Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo - PubMed (original) (raw)
Comparative Study
. 2001 May 15;166(10):6099-103.
doi: 10.4049/jimmunol.166.10.6099.
Affiliations
- PMID: 11342628
- DOI: 10.4049/jimmunol.166.10.6099
Comparative Study
Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo
M Li et al. J Immunol. 2001.
Abstract
To better understand the antigenic requirements for cross-presentation, we compared the in vivo efficiency of presentation of cell-associated vs soluble OVA with the OT-I (CD8) and OT-II (CD4) TCR transgenic lines. Cross-presentation of cell-associated OVA was very efficient, requiring as little as 21 ng of OVA to activate OT-II cells and 100-fold less to activate OT-I cells. In contrast, soluble OVA was presented inefficiently, requiring at least 10,000 ng OVA for activation of either T cell subset. Thus, cell-associated OVA was presented 500-fold more efficiently than soluble OVA to CD4 T cells and 50,000-fold more efficiently to CD8 T cells. These data, which represent the first quantitative in vivo analysis of cross-presentation, show that cell-associated OVA is very efficiently presented via the class I pathway.
Similar articles
- Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells.
Pooley JL, Heath WR, Shortman K. Pooley JL, et al. J Immunol. 2001 May 1;166(9):5327-30. doi: 10.4049/jimmunol.166.9.5327. J Immunol. 2001. PMID: 11313367 - Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.
Pouniotis DS, Esparon S, Apostolopoulos V, Pietersz GA. Pouniotis DS, et al. Immunol Cell Biol. 2011 Nov;89(8):904-13. doi: 10.1038/icb.2011.13. Epub 2011 Mar 8. Immunol Cell Biol. 2011. PMID: 21383765 - Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens.
Chung Y, Chang JH, Kim BS, Lee JM, Kim HY, Kang CY. Chung Y, et al. Eur J Immunol. 2007 Jun;37(6):1453-62. doi: 10.1002/eji.200636544. Eur J Immunol. 2007. PMID: 17474148 - Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.
Krishnan L, Sad S, Patel GB, Sprott GD. Krishnan L, et al. J Immunol. 2000 Nov 1;165(9):5177-85. doi: 10.4049/jimmunol.165.9.5177. J Immunol. 2000. PMID: 11046050 - The use of mouse models to better understand mechanisms of autoimmunity and tolerance.
Miyagawa F, Gutermuth J, Zhang H, Katz SI. Miyagawa F, et al. J Autoimmun. 2010 Nov;35(3):192-8. doi: 10.1016/j.jaut.2010.06.007. Epub 2010 Jul 23. J Autoimmun. 2010. PMID: 20655706 Free PMC article. Review.
Cited by
- Immune tolerance after delivery of dying cells to dendritic cells in situ.
Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM. Liu K, et al. J Exp Med. 2002 Oct 21;196(8):1091-7. doi: 10.1084/jem.20021215. J Exp Med. 2002. PMID: 12391020 Free PMC article. - Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines.
Petersen TR, Sika-Paotonu D, Knight DA, Simkins HM, Hermans IF. Petersen TR, et al. PLoS One. 2011 Mar 31;6(3):e17657. doi: 10.1371/journal.pone.0017657. PLoS One. 2011. PMID: 21483862 Free PMC article. - Autoimmunity in MFG-E8-deficient mice is associated with altered trafficking and enhanced cross-presentation of apoptotic cell antigens.
Peng Y, Elkon KB. Peng Y, et al. J Clin Invest. 2011 Jun;121(6):2221-41. doi: 10.1172/JCI43254. Epub 2011 May 2. J Clin Invest. 2011. PMID: 21537078 Free PMC article. - Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo.
Garulli B, Stillitano MG, Barnaba V, Castrucci MR. Garulli B, et al. Clin Vaccine Immunol. 2008 Oct;15(10):1497-504. doi: 10.1128/CVI.00166-08. Epub 2008 Aug 27. Clin Vaccine Immunol. 2008. PMID: 18753338 Free PMC article. - Canvassing Prospects of Glyco-Nanovaccines for Developing Cross-Presentation Mediated Anti-Tumor Immunotherapy.
Makandar AI, Jain M, Yuba E, Sethi G, Gupta RK. Makandar AI, et al. Vaccines (Basel). 2022 Nov 30;10(12):2049. doi: 10.3390/vaccines10122049. Vaccines (Basel). 2022. PMID: 36560459 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials